Navigation Links
Drug May Help Against Inflammatory Breast Cancer
Date:4/27/2009

Study shows those who respond to lapatinib survive longer,,,,

MONDAY, April 27 (HealthDay News) -- The drug lapatinib could be used to treat aggressive inflammatory breast cancer, suggest the findings of a phase 2 study.

Inflammatory breast cancer accounts for up to 6 percent of all invasive breast tumors in the United States and western Europe, according to the researchers. Symptoms include rapid onset of swelling, redness of breast skin, a pitted appearance caused by fluid under the skin of more than two-thirds of the breast, tenderness, hardening and warming of the breast.

For patients resistant to conventional anthracycline or taxane and trastuzumab, treatment options are limited. Lapatinib inhibits HER2, a protein that's expressed much more in inflammatory breast cancer than in other, less aggressive breast cancers.

The study included 126 women who took 1,500 milligrams of lapatinib once a day. None of them showed a full response to the drug, but 39 percent had a partial response, the researchers reported. Median progression-free survival was 15 weeks and, at 6 months, 22 percent of the women were still progression-free.

When the researchers divided the participants into four groups, they found that median overall survival was:

  • 18.4 months for those who responded to lapatinib after previous treatment with trastuzumab
  • 14 months for those who responded to lapatinib and had no previous trastuzumab treatment
  • 8.4 months for those unresponsive to lapatinib who had previously taken trastuzumab
  • 8.2 months for those unresponsive to lapatinib who had not previously taken trastuzumab.

The study found that 92 percent of the women had at least one adverse event, including shortness of breath and fluid around the lungs. Five participants died from adverse events that were possibly treatment related, said the Israeli and U.K. researchers.

"Patients who responded to treatment with lapatinib had a longer median overall survival than did those patients who did not respond, irrespective of previous exposure to trastuzumab," the researchers wrote. "Patients exposed to previous trastuzumab treatment who experienced a response to lapatinib had the longest median overall survival. This finding confirms the clinical benefit of targeted therapy in these patients."

"Lapatinib monotherapy is potentially clinically effective in heavily pretreated patients with inflammatory breast cancer with HER2+ tumors," they said. "The objective response rate noted ... coupled with the median duration of response and median overall survival supports a role for lapatinib in these patients."

The study appears online and in the June print issue of The Lancet Oncology.

More information

The U.S. National Cancer Institute has more about inflammatory breast cancer.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, April 26, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
3. Despite overeating, morbidly obese mice gain protection against diabetes
4. Alvarado Hospital Files Countersuit Against Blue Shield
5. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
6. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
7. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
8. $52.5 Million Settlement Against Sepracor Inc. Approved
9. The fight against colorectal cancer
10. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
11. Breastfeeding does not protect against asthma, allergies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug May Help Against Inflammatory Breast Cancer
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology: